Spinifex Pharmaceuticals is a clinical-stage Australian biotechnology company specialising in the development of products for the treatment of pain.
Additional Funding Round
Spinifex Pharmaceuticals announces it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest to fund the development of its pain management drug, EMA401.
Latest News & Events
16TH FEBRUARY 2012 Spinifex Wins a BioSpectrum Editor's Choice Award in the Category of 'BioSpectrum Asia-Pacific Emerging ... More
10TH JANUARY 2012 Spinifex presented at the Biotech Showcase 2012 conference in San Francisco ... More
6TH DECEMBER 2011 Appointment of Spinifex Non-Executive Chairman. ... More